Skip to main content

Table 1 Criteria for ruxolitinib failure in patients with MF—adapted from [52, 65]

From: Novel therapeutics in myeloproliferative neoplasms

Criteria Ruxolitinib duration Cytopenias Spleen size
Relapsed  ≥ 3 months Regrowth < 10% SVR or < 30% decrease in spleen size by palpation from baseline following an initial response
Refractory  ≥ 3 months  < 10% SVR or < 30% decrease in spleen size by palpation from baseline
Intolerant  ≥ 28 days New grade ≥ 3 thrombocytopenia, anemia, hematoma/hemorrhage or RBC transfusion requirement ≥ 2 units/month for 2 months
  1. SVR spleen volume reduction, RBC red blood cell